Streamlined Protein Structure Exploration: BioIn in PRinS3 Software Suite for Effortless Protein Refinement

Commencing on the fascinating world of in silico studies, our journey begins with the exploration and identification of protein targets.

Unveiling New Molecules: Boosting Disease Datasets in a scenario of limited availability of FDA-Approved Drugs using PRinS3 Platform.

The epidermal growth factor receptor (EGFR) is a key member in a group of receptors responsible for growth, carrying a built-in tyrosine kinase function.

Insilico Drug Repurposing Approach To Identify Drugs For The Treatment Of Neglected Diseases using PRinS3® Platform

Chagas Disease can be described as a condition in which the parasite named Trypanosoma cruzi is involved and is the main causative agent of this disease.

Identifying New Chemical Entities as Potential Therapeutic Agent for NAFLD Treatment using PRinS3® Platform

Non-alcoholic fatty liver disease, a chronic liver condition not caused by alcohol or other obvious liver-damaging factors, is characterized by excessive fat deposition in hepatocytes.

Exploring Natural Products that inhibit the Target Biliverdin Reductase in Hyperbilirubinemia using PRinS3® Platform

Hyperbilirubinemia is a form of illness characterized by an increase in blood bilirubin levels as a result of a failure to efficiently metabolize or eliminate bilirubin, a byproduct of erythrocyte breakdown. It can be traced back to irregularities in normal bilirubin metabolism.